The Clinical Research Coordinator (CRC) is primarily responsible for coordinating the operational aspects of ongoing clinical projects to ensure that the clients’ goals of time, cost, and quality are met. The CRC may serve as the primary contact with the client to ensure appropriate communications, project budget management, and meeting of timelines. The CRC may also serve as the project lead responsible for directing internal teams in the execution of the protocol and ensuring that all staff working on any given protocol have been properly delegated by the Principal Investigator and adequately trained on the protocol.
The position requires at least a Bachelor’s degree in one of the basic sciences or a related field.
Must have 3 years of experience as CRC and Phase 1 experience.
The position of CRC requires good management and organizational skills, understanding of medical procedures, exceptional interpersonal skills, the ability to work independently and lead a project specific team, strong computer skills and writing ability.
The CRC is expected to serve as the “command center” for assigned research studies, interacting extensively with sponsors, investigators, review boards, and study subjects.
The CRC exercises authority over research assistants (RAs) and medical techs during the course of research studies assigned to them and they are involved in study assignments and resource staffing for their projects.
The CRC must meet course requirements for Good Clinical Practices (GCPs), infection control, handling of hazardous materials, basic cardiac life support (BCLS), and other specific study-related training.
Clinilabs offers competitive benefits (medical/dental/vision), 401(k), employee discount program and paid time off. Visit www.clinilabs.com for more information.
Additional Salary Information: Salary will depend on skills and experience
Clinilabs is a premier full-service CRO that specializes in applying scientific principles to phase I and II studies in order to bring investigational products to the threshold of successful phase III trials. Our unique development strategy builds value into early phase development programs, carrying promising products forward swiftly and abandoning failures early. We enable our clients to apply their resources wisely and maximize the value of their drug and device portfolios.